TIBIDABO VENTURES - Investor Profile and Portfolio

Developer of ready-to-use kits for in vitro ADME-Tox market segment for research services. It provides cell-based in vitro kits that have patented gel-like cell culture medium, and shipping medium, which preserves cell functionality and viability at room temperature.

DRACONIS PHARMA is a developer of therapeutic solutions for the treatment of therapies for the treatment of cancer, pain, & other diseases. It has developed solutions for treating immune-based diseases such as inflammation, autoimmunity, allergy, cancer, pain, etc. It offers solutions to evaluate, the efficacy, safety, and toxicology of many types of compounds, such as small molecules, proteins, antibodies, RNA-based compounds, vaccines, functional foods, or probiotics. It has developed drug EP4 receptor antagonism for the response of the immune system.

Lykera is focussed on developing biologics for the treatment of cancer by targeting not only the tumour cells but also the stromal cells and tumour angiogenesis. Its lead product, LK-1 is a humanized MAb that targets three tumour compartments. The candidate is accompanied with the companion diagnostic kit and is ready to enter regulatory preclinical phases for treating solid tumors in pancreas and other organs. It also has two MAb candidates in the discovery phase for solid tumors.